Kura Oncology, Inc.’s Post

Could your patients be eligible for the KOMET-008 clinical trial aimed at evaluating ziftomenib, a menin inhibitor, with other existing standard-of-care treatments in relapsed or refractory acute myeloid leukemia? Hematologist-oncologist Harry Erba, MD, PhD, explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007. KOMET-008 is OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

Check out figure 7 in the discussion section. I love this figure and I had such a great time working on it! It took a while so I almost forgot about it. Such a lovely surprise to see this great paper is finally published!! (Link in the comments)

Today, we announced the first patient has been dosed in our KOMET-008 trial of our menin inhibitor ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC, for the treatment of relapsed or refractory acute myeloid leukemia.    Learn more about the KOMET-008 study and why we believe #ziftomenib has ideal properties as a combination agent for NPM1-mutant and KMT2A-rearranged #AML.   https://bit.ly/49t2TRA

🌟 Encouraging News in Leukemia Research! 🌟 The AML-ViVA trial, funded by the Anticancer Fund, reveals promising outcomes for Acute Myeloid Leukemia (AML) patients above 60 who don't respond to initial chemotherapy. The combination of azacitidine, pioglitazone, and all-trans retinoic acid proves safe and effective. Let's join efforts in spreading awareness for improved treatment options in AML. Read more about this trial: https://lnkd.in/eGr8BNmE #anticancerfund #CancerResearch #acutemyeloidleukemia University Hospital Regensburg Gauthier B.

KOMET-007 is actively recruiting patients with newly diagnosed or relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-007 is a Phase 1 study to assess the safety, tolerability, and preliminary clinical activity of ziftomenib in combination with venetoclax /-azacitadine, or standard induction cytarabine/daunorubicin (7 3) chemotherapy. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based #PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of #SJ45566, a potent and orally bioavailable LCK #PROTAC. #Protac #PDC #SmallMolecule #Medchem #Medcinal #FFS #FTE #CDMO #CMC

Guidelines for Venetoclax dosing in AML A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients https://lnkd.in/de8ZVUmZ

September 1st marks World CLL Day. CLL (chronic lymphocytic leukemia) is the most common form of leukemia, yet it is still rare with about 600-1000 patients receiving the diagnosis each year in Belgium.    At AstraZeneca, we are dedicated to addressing the needs of patients by providing a platform that brings information and patients together to ensure support, information and connection.  🔗 https://lnkd.in/gJ3cGcdU 🔗 https://lnkd.in/gvGyf2YH   Together, we can make a difference in the lives of those affected by CLL. AZ BeLux,  from hope, to impact.   #WCLLD24 #LetsLevelUp #CLL #FromHopeToImpact https://www.wclld.org/

📢 Congrats! Our client's research team published in #CancerResearch (IF=11.2) entitled "Foretinib ls Effective in Acute Myeloid Leukemia byInhibitingFLT3andOvercomingSecondaryMutations That DriveResistanceto Quizartiniband Gilteritinib". The research utilized TargetMol's three products: T3113 Foretinib: https://lnkd.in/eghs3RSs T2066 Quizartinib: https://lnkd.in/eedufhhH C0001 Protease inhibitor: https://lnkd.in/eHqMiYg4 They are choices made by the experts. You deserve to have it! ▶ Get the full article here: https://lnkd.in/eeRpU_VA ▶ For more information, please refer to the following image: #cancerresearch #smallmolecules #inhibitor #compounds #TargetMol